Akari Therapeutics (NASDAQ: AKTX) consolidates private placement closings, issues remaining ADSs
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Akari Therapeutics, Plc reported an amendment to its securities purchase agreement with certain investors for a previously announced private placement of American Depository Shares (ADSs) and related warrants. The amendment combines the originally planned second and third funding closings into a single consolidated closing.
The private placement covers 1,470,588 unregistered ADSs, or prefunded warrants to purchase ADSs, each ADS representing 80,000 ordinary shares, together with Series H, Series I and Series J warrants. On the June 26, 2026 combined closing date, Akari issued the remaining 980,395 ADSs or prefunded warrants due under the agreement.
Delivery of the Series H, Series I and Series J warrants to investors remains contingent on receiving shareholder approval at Akari’s annual general meeting scheduled for June 30, 2026. Other than changing the closing schedule, the amendment leaves all other purchase agreement terms unchanged.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Total ADSs in private placement: 1,470,588 ADSs
ADSs issued at combined closing: 980,395 ADSs
Ordinary shares per ADS: 80,000 ordinary shares per ADS
+2 more
5 metrics
Total ADSs in private placement
1,470,588 ADSs
Aggregate unregistered ADSs or prefunded warrants under the securities purchase agreement
ADSs issued at combined closing
980,395 ADSs
Remaining ADSs or prefunded warrants issued on June 26, 2026 combined closing date
Ordinary shares per ADS
80,000 ordinary shares per ADS
Each American Depository Share represents 80,000 Akari ordinary shares
Annual meeting date
June 30, 2026
Shareholder approval date required for delivery of Series H, I and J warrants
Amendment date
June 23, 2026
Date Akari and investors entered into the amendment to the purchase agreement
Key Terms
securities purchase agreement, American Depository Shares, prefunded warrants, Series H warrants, +1 more
5 terms
securities purchase agreement financial
"Akari Therapeutics, Plc entered into a securities purchase agreement with certain investors"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
prefunded warrants financial
"1,470,588 unregistered American Depository Shares (“ADSs”), or prefunded warrants to purchase ADSs"
Prefunded warrants are a security that gives the holder the right to convert the warrant into a share after paying a very small remaining amount because almost the full purchase price was paid upfront. They matter to investors because exercising them increases the company’s outstanding shares (dilution) and can provide immediate cash to the issuer while allowing holders to bypass ownership limits or simplify timing, similar to buying a nearly-complete gift card that only needs a tiny top-up to use.
Series H warrants financial
"together with Series H warrants, Series I warrants and Series J warrants to purchase an equivalent number of ADSs"
Series H warrants are tradable securities that give the holder the right, but not the obligation, to buy a company’s shares at a fixed price before a set expiration; the “Series H” label simply identifies a specific batch of warrants with its own terms. They matter to investors because exercising them increases the number of shares outstanding and can reduce each existing shareholder’s ownership, while also offering a way for warrant holders to lock in a future purchase price—similar to holding a coupon that lets you buy stock later at a preset rate.
emerging growth company regulatory
"Emerging growth company As previously disclosed on its"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Akari Therapeutics (AKTX) change in its securities purchase agreement?
Akari Therapeutics amended its securities purchase agreement to merge the planned second and third funding closings into one combined closing on June 26, 2026. All other economic and structural terms of the private placement remain unchanged under the original agreement.
How many Akari Therapeutics (AKTX) ADSs are involved in the private placement?
The private placement covers 1,470,588 unregistered American Depository Shares (ADSs) or prefunded warrants, with each ADS representing 80,000 ordinary shares. These securities are issued alongside Series H, Series I and Series J warrants to purchase an equivalent number of ADSs for participating investors.
How many Akari Therapeutics (AKTX) ADSs were issued at the combined closing?
At the June 26, 2026 combined closing, Akari issued and sold 980,395 ADSs, or prefunded warrants in lieu of ADSs, representing the remaining amount due under the purchase agreement. This followed an initial closing that occurred earlier on May 27, 2026.
What are the Series H, I and J warrants in the Akari Therapeutics (AKTX) deal?
The Series H, Series I and Series J warrants are instruments allowing investors to purchase an equivalent number of ADSs as in the private placement. They are issued together with the ADSs or prefunded warrants, but their actual delivery depends on receiving required shareholder approval.
Did the amendment change the economics of Akari Therapeutics’ (AKTX) private placement?
The amendment did not change the economics of Akari’s private placement; it only adjusted the timing of fundings by combining the second and third closings. The total number of ADSs, prefunded warrants and related Series H, I and J warrants remains as originally agreed.